Physician profile
Deborah Lynn Marcus
NPI 1932198033
$1,257.80
in general payments reported to CMS, 2019-2025
20 companies · $242 in 2025
The $242 reported for 2025 was more than what 79% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $19.11 · 2021: $208 · 2022: $174 · 2023: $136 · 2024: $282 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $369.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $207.94 | 2019-2025 | Pediarix, Bexsero, Rotarix |
| Cranial Technologies, INC | $83.64 | 2021-2025 | Doc Band |
| Phadia US INC. | $70.13 | 2019-2024 | Immunocap |
| Merck Sharp & Dohme LLC | $68.13 | 2022-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Ironshore Pharmaceuticals INC. | $66.29 | 2019-2024 | |
| Sanofi Pasteur INC. | $48.10 | 2021-2023 | |
| Tris Pharma INC | $47.16 | 2019-2021 | |
| Organon LLC | $42.85 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $41.78 | 2024-2025 | |
| Alk-Abello, INC | $37.61 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $34.31 | 2024 | Qelbree |
| Seqirus USA INC | $25.12 | 2025 | Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $19.11 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.60 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $18.33 | 2022 | |
| Shire North American Group INC | $18.18 | 2019 | |
| Kaleo, INC. | $14.66 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.37 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.